vs
Side-by-side financial comparison of CytoMed Therapeutics Ltd (GDTC) and LISATA THERAPEUTICS, INC. (LSTA). Click either name above to swap in a different company.
CytoMed Therapeutics Ltd is the larger business by last-quarter revenue ($115.4K vs $100.0K, roughly 1.2× LISATA THERAPEUTICS, INC.). CytoMed Therapeutics Ltd produced more free cash flow last quarter ($-855.4K vs $-16.0M).
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
GDTC vs LSTA — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $115.4K | $100.0K |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | — | -90.0% |
| Net Profit YoY | — | 35.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $100.0K | ||
| Q3 25 | — | $0 | ||
| Q2 25 | $115.4K | $70.0K | ||
| Q1 25 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | — | — | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-4.7M | ||
| Q1 25 | — | $-4.7M | ||
| Q3 24 | — | $-4.9M | ||
| Q2 24 | — | $-5.0M | ||
| Q1 24 | — | $-5.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -6954.3% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -6655.7% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.49 | ||
| Q2 25 | — | $-0.54 | ||
| Q1 25 | — | $-0.55 | ||
| Q3 24 | — | $-0.59 | ||
| Q2 24 | — | $-0.61 | ||
| Q1 24 | — | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $16.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $14.9M |
| Total Assets | — | $17.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.0M | ||
| Q3 25 | — | $19.0M | ||
| Q2 25 | — | $16.8M | ||
| Q1 25 | — | $20.2M | ||
| Q3 24 | — | $19.5M | ||
| Q2 24 | — | $28.3M | ||
| Q1 24 | — | $21.8M |
| Q4 25 | — | $14.9M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $21.0M | ||
| Q1 25 | — | $25.4M | ||
| Q3 24 | — | $33.7M | ||
| Q2 24 | — | $38.2M | ||
| Q1 24 | — | $43.0M |
| Q4 25 | — | $17.7M | ||
| Q3 25 | — | $21.8M | ||
| Q2 25 | — | $25.2M | ||
| Q1 25 | — | $29.0M | ||
| Q3 24 | — | $38.2M | ||
| Q2 24 | — | $42.6M | ||
| Q1 24 | — | $48.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-855.3K | $-15.9M |
| Free Cash FlowOCF − Capex | $-855.4K | $-16.0M |
| FCF MarginFCF / Revenue | -741.5% | -15977.0% |
| Capex IntensityCapex / Revenue | 0.0% | 28.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-15.9M | ||
| Q3 25 | — | $-3.3M | ||
| Q2 25 | $-855.3K | $-4.0M | ||
| Q1 25 | — | $-5.4M | ||
| Q3 24 | — | $-2.5M | ||
| Q2 24 | — | $-5.3M | ||
| Q1 24 | — | $-7.0M |
| Q4 25 | — | $-16.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-855.4K | — | ||
| Q1 25 | — | $-5.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -15977.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | -741.5% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 28.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
